SEOM clinical guidelines for endometrial cancer (2017)

Santaballa, Ana; Matías‐Guiu, Xavier; Redondo, Andrés; Carballo, N.; Gil, Miguel Gil; Gómez, César; Gorostidi, Mikel; Gutierrez, M. Tejedor; González-Martín, Antonio

doi:10.1007/s12094-017-1809-9

Cited by 31 publications

(38 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Endometrial cancer treatment often involves surgical removal of the uterus, ovaries, uterine tubes, and pelvic and paraaortic lymph nodes [40]. In the case of reproductive-aged women, fertility-sparing treatment is possible, however, it requires further standardization and development in order to provide the patient with access to various solutions [41,42]. It is important to look for complementary molecular markers that allow for an earlier and more precise diagnosis, as it can provide more treatment options and allow for the development of strategies that will be as non-invasive as possible for the patient.…”

Section: Discussionmentioning

confidence: 99%

“…Therapy selection and management protocol is closely related to the type, stage and grade of endometrial cancer, however, it is still not fully accurate. The Cancer Genome Atlas Research Network (TCGA) proposed an additional division of endometrial cancer into four molecular subtypes: POLE ultramutated, microsatellite instability hypermutated, copy number low, and copy number high, which emphasizes the high heterogeneity of this cancer [42]. Therefore, the classification of endometrial cancer taking into account changes at the molecular level is very important.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Interplay between miRNAs and Genes Associated with Cell Proliferation in Endometrial Cancer

Hermyt

Zmarzły

Grabarek

et al. 2019

IJMS

View full text Add to dashboard Cite

Endometrial cancer develops as a result of abnormal cell growth associated with uncontrolled cell proliferation, excessive activation of signaling pathways and miRNA activity. The aim of this study was to determine the expression profile of genes associated with cell proliferation and to assess which miRNAs can participate in the regulation of their expression. The study enrolled 40 patients with endometrial cancer and 10 patients without neoplastic changes. The expression profile of genes associated with cell proliferation and the expression profile of miRNAs were assessed using microarrays. RT-qPCR was performed to validate mRNA microarray results. The mirTAR tool was used to identify miRNAs that regulate the activity of genes associated with cell proliferation. Decreased expression of IGF1 and MYLK, as well as SOD2 overexpression, were observed in endometrial cancer using both mRNA microarrays and RT-qPCR. Microarray analysis showed low levels of NES and PRKCA, but this was only partially validated using RT-qPCR. Reduced activity of MYLK may be caused by increased miR-200c, miR-155 and miR-200b expression. Cell proliferation is disturbed in endometrial cancer, which may be associated with an overexpression of miR-200a, miR-200c, and miR-155, making it a potential diagnostic marker.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Interplay between miRNAs and Genes Associated with Cell Proliferation in Endometrial Cancer

Hermyt

Zmarzły

Grabarek

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…Nonetheless, this may reinforce the therapeutic benefit of LND specifically in advanced bulky nodal disease. For stage III EC, the ESMO-ESGO-ESTRO 2016 (5) supported by the newer SEOM guidelines (40) recommend radical cytoreductive surgery (debulking), which is defined as reducing the volume of a tumour to the greatest extent possible (41) . The Gynaecologic Oncology Group (GOG) recommends reducing gross residual disease to [?…”

Section: The Role Of Lymph Node Dissection In Advanced Endometrial Camentioning

confidence: 99%

“…Surgical Method: Minimally invasive surgery (MIS) is preferred over laparotomy based on ESMO-ESGO-ESTRO 2016 (5,(36)(37)(38) while laparotomy is preferred for complex cases (39) . Within MIS, robotic and laparoscopic LND shows similar adequacy (38)(39)(40) while robotic has certain advantages over laparoscopic surgery (38,41,42) . Role of sentinel lymph node (SLN) dissection: ESMO-ESGO-ESTRO recognises SLN algorithms as a potential alternative to systematic LND in early stage EC (5,43) supported by recent studies (23,36,44) .…”

Section: Perspective Title Perspectives Summarymentioning

confidence: 99%

The role of lymph node dissection in endometrial cancer: a systematic scoping review.

Kufour¹,

Thornton-Wood²,

Allen³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Surgical staging including lymph node dissection (LND) is considered the gold standard method of evaluating LN status and guiding adjuvant therapy in endometrial cancer (EC). The standard surgical treatment of EC includes systematic LND, which is associated with morbidity. Consequently, there is debate weighing the risks and benefits of LND. Objectives: To evaluate the role of LND in all stages of EC. Search Strategy: Systematic search of MEDLINE up to 9th January 2020 including references of relevant studies. Selection Criteria: Published literature in English describing LND in EC. Data Collection and Analysis: 176 articles were screened by title and abstract to select those describing roles of LND in EC. Main Results: We confirmed the diagnostic role of LND and the benefits of risk stratifying early-stage EC patients, despite variations in stratification systems. Low and high-risk groups have well-established guidelines. The role of LND remains controversial in intermediate and high-intermediate risk groups. Sentinel lymph node dissection seems promising to prevent under-/overtreatment. In all risk groups, the prognostic role of LND is well-understood however therapeutic use is debatable. In most stages of advanced EC, LND is beneficial, except for non-bulky nodal disease. Variation exists in what constitutes adequate LN counts, targets and surgical methods. Conclusions: International standardisation of the definition of LND and further adoption of sentinel lymph node algorithms is required. Future research should investigate the need to stratify for bulky and non-bulky nodal disease in advanced EC. New RCTs are needed to guide revaluation of the ESMO-ESGO-ESTRO 2016 guidelines. Funding There were no costs associated with conducting or writing this review.

show abstract

“…Endometrial cancer guidelines summarized best evidence about adjuvant chemotherapy in high-risk patients [5]. Clinical guidelines in rare tumors are a highly valued tool for Spanish medical oncologists in their daily practice.…”

mentioning

confidence: 99%